IMRN (Immuron Ltd) Pangali Forward P/E

Immuron Limited is developing its mature Travelan product line by expanding its sales markets. Growth is supported by R&D contracts with the US Army to create hyperimmune milk. The company's forward P/E dynamics reflect the real-time valuation of the business, with the value stabilizing at 0.00. However, fierce competition for pharmacy shelf space with dietary supplement and probiotic manufacturers creates significant risks for the brand's expansion.

IMRN - Kapitalisasi marang proyeksi bathi Immuron ing rentang 04.07.2022 - 10.11.2026

Rincian analitis lan laporan data perusahaan Immuron Inc (IMRN)

- rega saiki lan proyeksi nilai saham:

Kutipan saham Immuron Limited|IMRN - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Immuron Ltd|IMRN - Nilai Perusahaan Nalika Diakuisisi Penuh

- informasi kapitalisasi buku:

Nilai Buku saben Saham Immuron|IMRN - Pambiji Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih immuron.com.au|IMRN - Aset Agregat Bisnis

- data utang lan likuiditas:

Total Utang marang Modal Immuron Limited|IMRN - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Immuron Limited|IMRN - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Immuron Ltd|IMRN - Kewajiban jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Immuron|Likuiditas cepet immuron.com.au

- statistik bathi lan rasio pasar:

IMRN - Bathi pungkasan|Bathi sing dikarepake Immuron Limited|IMRN - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Immuron Limited|IMRN - Rasio P/E diaturake wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Immuron Ltd|IMRN - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Immuron|IMRN - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan immuron.com.au|IMRN - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Immuron Limited

Analisis fundamental perusahaan:IMRN Immuron

Immuron Limited revenues depend on global tourism flows and the efficiency of distributing antibacterial drugs through pharmacy retail. The ratio of the current share price to projected earnings allows for an assessment of the premium paid for future business success; therefore, the company's future P/E trajectory serves as an indicator of the balance between market expectations and the issuer's actual ability to generate cash flow.

Pesaing Immuron Limited

Prakiraan rega marang bathi PHAT (Phathom Pharmaceuticals, Inc.)|TERN (Terns Pharma) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E IRWD (Ironwood Pharmaceuticals, Inc.)|Pangali forward rega marang bathi Curanex Pharma|Evoke Pharma, Inc. - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi Entero Therapeutics, Inc. ENTO|RDHL (redhillbio.com) - Prakiraan rega marang bathi|PALI: Rasio kapitalisasi marang bathi mangsa ngarep|JAGX (Jaguar Animal Health) - Pangali Forward P/E|Biora Therapeutics, Inc (BIOR) - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Morphic Holding, Inc. (MORF)